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The Immunopharmacology Research Group, University of Tampere School of Medicine, and Tampere
University Hospital, Tampere, Finland
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Abstract
Mitogen-activated protein kinase phosphatase 1 (MKP-1) expression is induced by inflam-
matory factors, and it is an endogenous suppressor of inflammatory response. MKP-1
expression is increased by PDE4 inhibitor rolipram suggesting that it is regulated by cAMP-
enhancing compounds. Therefore, we investigated the effect of β2-receptor agonists on
MKP-1 expression and inflammatory response. We found that β2-receptor agonists salbuta-
mol and terbutaline, as well as 8-Br-cAMP, increased MKP-1 expression. Salbutamol and
terbutaline also inhibited p38 MAPK phosphorylation and TNF production in J774 mouse
macrophages. Interestingly, salbutamol suppressed carrageenan-induced paw inflamma-
tion in wild-type mice, but the effect was attenuated in MKP-1(-/-) mice. In conclusion, these
data show that β2-receptor agonists increase MKP-1 expression, which seems to mediate,
at least partly, the observed anti-inflammatory effects of β2-receptor agonists.
Introduction
Mitogen-activated protein kinases (MAPKs) are important intracellular signaling pathways
that regulate many physiological and pathophysiological events in cells. The three main MAPK
pathways include p38 MAPK, Jun N-terminal kinase (JNK) and extracellular signal-regulated
kinase (ERK) [1,2]. MAPK pathways are three-tier kinase cascades that are activated in
response to several extracellular signals, such as cytokines, growth factors and bacterial sub-
stances through G-protein-coupled and/or kinase-linked receptors. Upon activation, threonine
and tyrosine residues in the activation motif of the given MAPK are phosphorylated by the
upstream kinase in the signaling cascade [3,4]. Targets of activated MAPKs include transcrip-
tion factors and other regulatory proteins, and they regulate many physiological cellular pro-
cesses, such as cell growth, proliferation, differentiation, motility, stress response, survival, and
apoptosis [1,2]. p38 MAPK and JNK have also a marked role in inflammation and immune
response. They regulate the production of inflammatory cytokines, such as tumor necrosis fac-
tor (TNF), interleukin-6 (IL-6) and other mediators, such as prostaglandins and nitric oxide.
Also, p38 MAPK and JNK augment Th1 type immune response and support the activation and
functions of Th1 cells [1,5,6].
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Dual specificity phosphatases (DUSPs) are endogenous factors that dephosphorylate tyro-
sine and threonine residues of their target proteins. Mitogen-activated protein kinase phospha-
tases (MKPs) are a subgroup of DUSPs, and they specifically dephosphorylate MAPKs, which
makes them endogenous suppressors of activated MAPK pathways. MKP family of phospha-
tases has eleven members, and they display differences in substrate specificity among MAPKs,
as well as in tissue distribution, cellular location and expressional pattern [7,8]. MAP kinase
phosphatase 1 (MKP-1) is a nuclear phosphatase and it regulates p38 MAPK, and in some
cells, JNK activity [6,9]. It has earlier been shown that hypoxia and inflammatory signals
increase MKP-1 expression [10], and by inhibiting p38 MAPK, MKP-1 suppresses inflamma-
tory gene expression and attenuates inflammatory response [11,12]. Interestingly, MKP-1 has
also been reported to mediate certain anti-inflammatory drug effects. MKP-1 expression is
increased by glucocorticoids and anti-rheumatic gold-compounds, and MKP-1 mediates, in
part, the anti-inflammatory effects of these drugs [13,14]. Recently, we demonstrated that
phosphodiesterase (PDE) 4 inhibitor rolipram increased MKP-1 levels and suppressed inflam-
matory response in wild-type mice, but the response was impaired in MKP-1(-/-) mice [15].
Salbutamol and terbutaline are β2-receptor agonists used in the treatment of obstructive
lung diseases as bronchodilating remedy. β2-receptors are G protein-coupled receptors and
their activation stimulates Gs-proteins leading to increased adenylate cyclase activity and eleva-
tion of cAMP levels in cells [16–18]. In addition to their bronchodilation effects, β2-receptor
agonists have been shown to possess certain anti-inflammatory properties in immune and
inflammatory cells, which effects may contribute to the therapeutic drug effects in the treat-
ment of inflammatory lung diseases. In experimental acute lung injury, β2-receptor agonists
have been reported for example to attenuate proinflammatory activity and neutrophil recruit-
ment. Combinations of β2-receptor agonists’ bronchodilatory and anti-inflammatory proper-
ties improve the value of these drugs in the treatment of acute and chronic lung diseases [19].
Because MKP-1 promotor contains a cAMP response element CRE [20,21], we hypothesized
that cAMP elevating β2-receptor agonists may regulate the expression of this important endog-
enous anti-inflammatory factor. In the present study we investigated the effects of salbutamol
on MKP-1 expression and further, whether MKP-1 is involved in the anti-inflammatory effects
of this β2-receptor agonist.
Methods
Materials
Reagents were obtained as follows. Salbutamol [α-((tert-butylamino)methyl)-4-hydroxy-m-
xylene-α,α´-diol], terbutaline [5-(2-(tert-butylamino)-1-hydroxyethyl)benzene-1,3-diol],
8-Br-cAMP (8-bromoadenosine 3´,5´-cyclic monophosphate) and LPS from Escherichia coli
strain 0111:B4 were purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). Rolipram [4-
(3-cyclopentyloxy-4-methoxy-phenyl)-pyrrolidin-2-one] and BIRB 769 [1-(5-tert-butyl-2-p-
tolyl-2H-pyrazol-3-yl)-3(4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl)urea] were obtained
from Axon Medchem BV (Groningen, the Netherlands). All other reagents were purchased
also from Sigma-Aldrich Inc. (St. Louis, MO, USA) unless otherwise stated below.
Cell culture
J774 mouse macrophages (ATCC, Rockville Pike, MD, USA) were cultured at +37°C in 5%
CO2 atmosphere in Dulbecco´s Modified Eagle´s Medium supplemented with glutamax-1
(DMEM; Invitrogen, Paisley, UK) containing 10% (v/v) heat-inactivated FBS (fetal bovine
serum), 100 U/ml penicillin, 100 μg/ml streptomycin and 250 ng/ml amphotericin B (all from
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Abbreviations: COPD, chronic obstructive
pulmonary disease; CRE, cAMP responsive element;
CREB, cAMP responsive element binding protein;
DUSP, dual-specificity phosphatase; ERK,
extracellular-regulated kinase; IL, interleukin; LPS,
lipopolysaccharide; JNK, Jun N-terminal kinase;
MAPK, mitogen-activated protein kinase; MKP,
mitogen-activated protein kinase phosphatase; PDE,
phosphodiesterase; TNF, tumor necrosis factor.
Gibco, Wien, Austria). For experiments, cells (2.5 x 105 cells/well) were seeded on 24-well
plates and the cell monolayers were grown for 72 h before the experiments were started.
Salbutamol, terbutaline and rolipram were dissolved in dimethyl sulfoxide (DMSO), and
8-Br-cAMP and LPS in phosphate buffered saline (PBS). LPS (10 ng/ml) and/or the com-
pounds of interest at the concentrations indicated or the solvent (DMSO, 0.1% v/v) were added
to the cells in fresh culture medium containing 10% FBS and the supplements. Cells were fur-
ther incubated for the time indicated.
The effect of LPS and the tested chemicals on cell viability was evaluated by modified XTT
test (Cell Proliferation Kit II; Roche Diagnostics, Mannheim, Germany). Neither LPS nor the
other chemicals used in the experiments were observed to evoke cytotoxicity.
Preparation of cell lysates andWestern blot analysis
At the indicated time points, culture medium was removed. Cells were rapidly washed with
ice-cold phosphate-buffered saline (PBS) and solubilized in cold lysis buffer containing 10 mM
Tris-HCl, 5 mM EDTA, 50 mMNaCl, 1% Triton X-100, 0.5 mM phenylmethylsulfonyl fluo-
ride, 1 mM sodiumorthovanadate, 20 μg/ml leupeptin, 50 μg/ml aprotin, 5 mM sodium fluo-
ride, 2 mM sodium pyrophosphate and 10 μM n-octyl-β-D-glucopyranoside. After incubation
for 20 min on ice, lysates were centrifuged (12 000 g, 10 min, +4°C) and supernatants were col-
lected and mixed in a ratio 1:4 with SDS loading buffer (62.5 mM Tris-HCl, pH 6.8, 10% glyc-
erol, 2% SDS, 0.025% bromophenol blue and 5% β-mercaptoethanol) and stored at -20°C until
analyzed. Protein concentrations in the samples were measures by the Coomassie Brilliant Blue
method (Coomassie Protein Assay Reagent Kit; Pierce, Rockford, IL, USA).
Before Western blot analysis, the samples were boiled for 10 min. Equal aliquots of protein
(20 μg) were loaded on 12% SDS-polyacrylamide gels and separated by electrophoresis. Proteins
were transferred to Hybond enhance chemiluminescence nitrocellulose membrane (Amersham
Biosciences, Buckinghamshire, UK) by semi-dry electroblotting. After transfer the membrane was
blocked in TBS/T [20 mM Tris-base (pH 7.6), 150 mMNaCl, 0.1% Tween-20] containing 5%
non-fat milk for 1 h at room temperature. For detection of phosphorylated proteins, membranes
were blocked in TBS/T containing 5% bovine serum albumin (BSA). Membranes were incubated
overnight at +4°C with the primary antibody and at room temperature for 1 h with the secondary
antibody, and the chemiluminescent signal was detected by ImageQuant™ LAS 4000 mini (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden). The chemiluminescent signal was quantified with
FluoChem program (version 3.1) and Image Quant TL 7.0 Image Analysis software.
Following antibodies were used in the Western blot analysis: MKP-1 (SAB2500331; Sigma-
Aldrich Inc., St. Louis, MO, USA), p38 MAPK (ab27986; Abcam, Cambridge, UK) and phos-
pho-p38 MAPK (#9211; Cell Signaling Technology Inc., Beverly, MA, USA), as well as actin
(sc-1615), polyclonal anti-goat (sc-2020) and polyclonal anti-rabbit (sc-2004) (all three from
Santa Cruz Biotechnology, Santa Cruz, CA, USA).
RNA extraction and quantitative real-time reverse transcription
polymerase chain reaction (qRT-PCR)
At the indicated time points, the culture medium was removed, and cell homogenization and
total RNA extraction was carried out by using GenEluteTM Mammalian Total RNAMiniprep
Kit (Sigma-Aldrich Inc., St. Louis, MO, USA) according to the manufacturer´s instructions.
Reverse transcription of RNA to cDNA was performed by TaqMan1 Reverse Transcription
Reagent kit (Applied Biosystems, Foster City, CA, USA), according to the supplier´s instruc-
tions. The primer and probe sequences and concentrations were optimized according to the
manufacturer´s guidelines in TagMan1 Universal PCR Master Mix Protocol part number
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4304449 revision C (Applied Biosystems, Branchburg, NJ, USA). The following primer and
probe sequences were used: for mouse MKP-1 5´-AAGGATGCTGGAGGGAGAGT-3´
(forward), 5´-TGAGGTAAGCAAGGCAGATGGT-3´ (reverse) and 5´-TTTGTTCATTGC
CAGGCCGGCAT-3´ (probe containing 6-FAM as the 5´-reporter dye and TAMRA as the
3´-quencher); for mouse TNF 5´-AATGGCCTCCCTCTCATCAGTT-3´ (forward), 5´-TCCT
CCACTTGGTGGTTTGC-3´ (reverse) and 5´-CTCAAAATTCGAGTGACAAGCCTGTAGC
CC-3´ (probe containing 6-FAM as the 5´-reporter dye and TAMRA as the 3´-quencher); for
mouse GAPDH 5´-GCATGGCCGGCCGTGTTC-3´ (forward), 5´-GATGTCATCATACTT
GGCAGGTTT-3´ (reverse) and 5´- TCGTGGATCTGACGTGCCGCC-3´ (probe containing
6-FAM as the 5´-reporter dye and TAMRA as the 3´-quencher). Primers and probes were
obtained fromMetabion (Martinsried, Germany).
PCR reaction parameters were as follows: incubation at +50°C for 2 min and at +95°C for
10 min, and thereafter 40 cycles of denaturation at +95°C for 15 s and annealing and extension
at +60°C for 1 min. Each sample was determined in duplicate. A standard curve method was
used to estimate the relative mRNA levels. When calculating the results, MKP-1 and TNF
mRNA levels were first normalized against GAPDH.
Enzyme-Linked Immunosorbent Assay (ELISA)
Culture medium samples and cell lysates were kept at -20°C until assayed. The concentrations
of mouse TNF (Duoset1 ELISA Development System mouse TNF kit; R&D Systems Europe
Ltd., Abindgon, UK) and mouse cAMP (cAMP ELISA Kit; Cell Biolabs, Inc. San Diego, CA,
USA) were determined by ELISA according to the manufacturer´s instructions.
Animals
Carrageenan-induced paw edema was carried out in wild-type and MKP-1(-/-) C57BL/6 mice.
The MKP-1 deficient mice were originally generated in the laboratory of R. Bravo at Bristol-
Myers Squibb Pharmaceutical Research Institute (Princeton, NJ, USA) and those as well as corre-
sponding wild-type mice were bred at the University of Tampere School of Medicine animal
facilities under conditions of optimum light (12:12 light-dark cycle), temperature (+22 ± 1°C)
and humidity (50–60%), and food and water provided ad libitum. The study was approved by
the National Animal Experiment Board. Female mice aged 10–12 weeks were used in the study.
Carrageenan-induced paw edema
MKP-1 deficient and wild-type C57BL/6 mice (20–25 g) were divided into groups of six mice
and treated with 200 μl of PBS or salbutamol (5 mg/kg in PBS) [22,23] by an i.p. injection 2 h
before applying carrageenan. Before the administration of carrageenan, the mice were anaes-
thetized by i.p. injection of 0.5 mg/kg of medetomidine (Domitor1 1 mg/ml; Orion Oyj,
Espoo, Finland) and 75 mg/kg of ketamine (Ketalar1 10 mg/ml; Pfizer Oy Animal Health, Hel-
sinki, Finland). The mice received a 45 μl i.d injection of λ-carrageenan (2% dissolved in nor-
mal saline) in one hind paw. The contralateral paw received 45 μl of saline and it was used as a
control. Paw volume was measured before and 2 h, 4 h and 6 h after the carrageenan injection
with a plethysmometer (Ugo Basile, Comerio, Italy). Edema is expressed as the difference
between the volume changes of the carrageenan-treated paw and the control paw.
Statistics
Results are expressed as mean ± standard error of mean (S.E.M.). When appropriate, Student´s
t-test, one-way ANOVA with Dunnett´s or Bonferroni´s post test or two-way ANOVA with
Anti-Inflammatory Effects of Beta2-Agonists Are Mediated by MKP-1
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Bonferroni´s post test was performed using GraphPad Prism-5 version 5.04 for Window XP
(GraphPad Software Inc., La Jolla, CA, USA). P values less than 0.05 were considered significant.
Results
β2-receptor agonists salbutamol and terbutaline enhanced MKP-1
expression in activated mouse macrophages
MKP-1 promoter has been described to contain cis-regulator CRE sequences [20,21]. Therefore
we hypothesized that cAMP-elevating compounds would regulate MKP-1 expression. As
expected, β2-receptor agonist salbutamol increased intracellular cAMP levels in J774 macro-
phages (Table 1). Next, we investigated the effects of salbutamol on MKP-1 expression in these
cells. MKP-1 mRNA expression was increased by LPS and, interestingly, it was further enhanced
by salbutamol and by a cAMP analog 8-Br-cAMP (Fig 1). Salbutamol and another β2-receptor
agonist terbutaline increased MKP-1 expression alone and in combination with LPS in J774 mac-
rophages in a dose-dependent manner (Fig 2). MKP-1 is an endogenous suppressor of p38
MAPK activity. Therefore, we investigated the effect of β2-receptor agonists salbutamol and ter-
butaline on p38 MAPK phosphorylation. The phosphorylation of p38 MAPK was increased in
response to LPS and it was inhibited by β2-receptor agonists in J774 macrophages (Fig 3).
β2-receptor agonists salbutamol and terbutaline inhibited TNF
production in activated mouse macrophages
TNF is a cytokine whose expression is known to be regulated by MKP-1 and p38 MAPK
[15,24]. Therefore, we continued by investigating the effects of β2-receptor agonists on TNF
production. Salbutamol and terbutaline as well as cAMP analog 8-Br-cAMP inhibited LPS-
induced TNF mRNA and protein expression, and maximal/submaximal inhibition of TNF
protein release was observed with 100 nM drug concentration in J774 macrophages (Fig 4).
TNF production was further inhibited when salbutamol or terbutaline was combined with a
PDE4 inhibitor rolipram (Fig 4E). We also investigated the effect of p38 MAPK inhibitor on
TNF production. As expected, p38 MAPK inhibitor BIRB 796 inhibited LPS-induced TNF
release in macrophages (Fig 4F).
The inhibition of carrageenan-induced paw inflammation by salbutamol
was mediated by MKP-1
As salbutamol increased MKP-1 expression, we wanted to investigate whether MKP-1 could
mediate the anti-inflammatory effects of salbutamol, therefore we tested the effect of
Table 1. Salbutamol increased intracellular cAMP levels in J774 macrophages.
treatment cAMP (pg/ml)
Control 1.08 ± 0.8
Salb 100 nM 1230.9 ± 251.8 a
LPS 10 ng/ml 20.6 ± 11.1
LPS+ Salb 730.5 ± 246.5 b
J774 macrophages were incubated with salbutamol (Salb) and stimulated with LPS for 1 min. Cells were
then lysed and cAMP levels were measured by ELISA. Results are expressed as mean ± S.E.M, n = 5.
One-way ANOVA with Bonferroni´s post test was performed, and statistical signiﬁcance is (a) p < 0.001
between untreated cells and cells treated with salbutamol and (b) p < 0.001 between LPS-treated cells and
cells treated with the combination of LPS and salbutamol.
doi:10.1371/journal.pone.0148144.t001
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Fig 1. Salbutamol and cAMP analog 8-Br-cAMP enhanced MKP-1 expression in J774macrophages. J774 macrophages were stimulated with LPS (10
ng/ml) in the presence or in the absence of salbutamol (A) or 8-Br-cAMP (B) for the time indicated. MKP-1 mRNA was measured by quantitative RT-PCR,
and MKP-1 mRNA expression levels were normalized against GAPDHmRNA levels. Results are expressed as mean ± S.E.M., n = 3. One-way ANOVA with
Dunnett´s post test was performed, and statistical significance is indicated with * p < 0.05 and ** p < 0.01 as compared to control cells.
doi:10.1371/journal.pone.0148144.g001
Anti-Inflammatory Effects of Beta2-Agonists Are Mediated by MKP-1
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Fig 2. Salbutamol and terbutaline enhanced MKP-1 expression in J774macrophages in a dose-
dependent manner. (A and B) J774 macrophages were treated with increasing concentrations of salbutamol
or terbutaline in the absence or in the presence of LPS (10 ng/ml) for 1 h. MKP-1 mRNA was measured by
quantitative RT-PCR, and MKP-1 mRNA expression levels were normalized against GAPDHmRNA levels.
(C) J774 cells were incubated with LPS (10 ng/ml) and salbutamol (100 nM) for 1 hour and MKP-1 protein
was measured byWestern blot. The chemiluminescent signal was quantified, and the amounts of MKP-1
Anti-Inflammatory Effects of Beta2-Agonists Are Mediated by MKP-1
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salbutamol on the severity of carrageenan-induced paw inflammation in wild-type and
MKP-1(-/-) mice. Carrageenan-induced paw edema was increased in MKP-1(-/-) mice as com-
pared to wild-type mice (AUC values were 186.7 ± 13.1 μL/h and 236.7 ± 15.9 μL/h in WT and
MKP-1(-/-) mice, respectively, p = 0.0352, n = 6, Fig 5). Carrageenan-induced paw edema was
clearly attenuated by salbutamol in wild-type mice (73% reduction in AUC value), while salbu-
tamol was less effective to reduce paw edema in MKP-1(-/-) mice (43% reduction in AUC
value, p = 0,0148) (Fig 5).
Discussion
The aim of the present study was to investigate the effects of β2-receptor agonist salbutamol on
MKP-1 expression, on TNF production and on acute inflammatory response in vivo. We
found that salbutamol increased MKP-1 expression, inhibited the phosphorylation of p38
MAPK and suppressed the production of TNF. We used another β2-receptor agonist terbuta-
line as a reference compounds and its effects on p38 MAPK phosphorylation and TNF produc-
tion were comparable to those of salbutamol. Salbutamol suppressed carrageenan-induced
acute inflammation in vivo in wild-type mice, but that effect was attenuated in MKP-1(-/-)
mice in a statistically significant manner. These results suggests that acute anti-inflammatory
effects of β2-receptor agonists are partly mediated by MKP-1.
β2-receptor agonists are used as a bronchodilators in obstructive lung diseases [17,19]. β2-
receptor agonists have been reported to have anti-inflammatory effects in addition to their
effects on smooth muscle relaxation in the airways. They have been shown to inhibit the
expression of inflammatory mediators and to reduce capillary permeability and formation of
plasma exudate and tissue edema [25,26]. Salbutamol also reduced carrageenan-induced paw
edema in rats and that effect was attenuated when the β2-receptors were blocked by a non-
selective β-receptor antagonist propranolol [27]. In this study, we found that β2-receptor ago-
nists salbutamol and terbutaline inhibited the production of TNF in macrophages. We also
found that carrageenan-induced paw edema was reduced by salbutamol, which is in line with
the previous studies in rats [27]. These results show that β2-receptor agonists have anti-inflam-
matory effects in vitro and in vivo, and these findings are in line with the previously published
reports.
MKPs belong to a larger family of DUSPs, and they are endogenous suppressors of MAPK
activity [28,29]. MKPs control MAPK activity by dephosphorylating the activation domain
(Thr-X-Tyr, threonine and tyrosine residues) of MAPK, which inactivates the kinase. MKPs
regulate the inflammatory response as well as other cellular functions including apoptosis, cell
cycle, proliferation and differentiation [7,30].
MKP-1 is an interesting member of the MKP phosphatase family. MKP-1 is expressed in
most cell types and tissues in human body. It is a nuclear tyrosine/threonine phosphatase that
regulates primarily the activity of p38 MAPK, and in some cells, JNK [5,31]. p38 MAPK path-
way is an important regulator of inflammation and immune response [2]. p38 MAPK inhibi-
tors attenuate the production of inflammatory mediators [11,31–33], and they have clear anti-
inflammatory effects in experimental models of inflammatory diseases [34–36]. Studies with
MKP-1(-/-) mice have shown that MKP-1 suppresses inflammatory gene expression (such as
TNF and IL-6), and attenuates acute and chronic inflammatory response by inhibiting p38
MAPK [11,12,31,37]. Despite excessive inflammatory response, MKP-1(-/-) mice display
were normalized against actin. Results are expressed as mean ± S.E.M., n = 6 (A and B) or n = 4 (C). One-
way ANOVA with Dunnett´s (A and B) or Bonferroni´s (C) post test was performed, and statistical significance
is indicated with * p < 0.05, ** p < 0.01 and *** p < 0.001 as compared to control or LPS-treated cells.
doi:10.1371/journal.pone.0148144.g002
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Fig 3. Salbutamol and terbutaline reduced the phosphorylation of p38 MAPK in J774 macrophages.
J774 macrophages were stimulated with LPS (10 ng/ml) in the absence or in the presence of salbutamol
(100 nM, A) or terbutaline (100 nM, B) for 1 h, and the phosphorylation of p38 MAPK was detected by
Western blot. The chemiluminescent signal was quantified, and phosphorylated p38 MAPK was normalized
against total p38 MAPK. Results are expressed as mean ± S.E.M, n = 8. One-way ANOVA with Bonferroni´s
post test was performed, and statistical significance is indicated with *** p < 0.001 as compared to LPS-
treated cells.
doi:10.1371/journal.pone.0148144.g003
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Fig 4. Salbutamol, terbutaline, 8-Br-cAMP and the p38 MAPK inhibitor BIRB 769 inhibited TNF production in J774macrophages. J774 macrophages
were stimulated with LPS (10 ng/ml) in the absence or in the presence of salbutamol (A, C and E), terbutaline (B, C and E), 8-Br-cAMP (C and D), rolipram (E)
or the p38 MAPK inhibitor BIRB 769 (F) for 24 h (A, B, D, E and F; TNF protein) or for 4 h (C; TNFmRNA). TNF mRNA was measured by quantitative
Anti-Inflammatory Effects of Beta2-Agonists Are Mediated by MKP-1
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defective anti-microbial responses due to reduced IL-12 production, impaired Th1 response
and excessive IL-10 release [38–40]. Interestingly, in ovalbumin-induced airway inflammation
model, a common experimental asthma model, the increased activation of p38 MAPK coincide
with the decreased expression of MKP-1 [41].
RT-PCR and TNFmRNA expression levels were normalized against GAPDHmRNA levels. TNF protein accumulation in the culture medium was measured
by ELISA. Results are expressed as mean ± S.E.M., n = 8 (A-C) or n = 4 (D, E and F). One-way ANOVA with Dunnett´s post test (A and B) or Bonferroni´s
post test (C-F) was performed and statistical significance is indicated with * p < 0.05, ** p < 0.01 and *** p < 0.001 as compared to LPS-treated cells. In the
Panel 4E, statistical significance (a) is p < 0.001 between LPS+ salbutamol and LPS+ salbutamol+ rolipram treated cells, and (b) is p < 0.001 between LPS
+ terbutaline and LPS+ terbutaline+ rolipram treated cells.
doi:10.1371/journal.pone.0148144.g004
Fig 5. Salbutamol attenuated carrageenan-induced paw inflammation in mice.Mice were treated with salbutamol (5 mg/kg, i.p.) 2 h before the
experiment. In the beginning of the experiment (0 h), hind paw volumes were measured with a plethysmometer. After that, carrageenan (2%) or vehicle
(control) was injected into the paw and the paw edema was measured with plethysmometer at the time points indicated. Edema is expressed as the
difference between the volume changes of the carrageenan-treated paw and the control paw. Mean ± S.E.M., n = 6. The Fig 5C presents the percent
decrease in AUC values by salbutamol.
doi:10.1371/journal.pone.0148144.g005
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cAMP is an important intracellular second messenger that mediates many effects of β2-
receptor agonists. MKP-1 promoter contains two binding sites for the transcription factor
cAMP responsive element binding protein (CREB) [20]. We found that salbutamol enhanced
cAMP level in macrophages, and that cAMP analog 8-Br-cAMP enhanced MKP-1 expression
as did β2-receptor agonists. cAMP has been reported to increase the expression of MKP-1 by
activating protein kinase A-CREB pathway [15,42–45].
Suppression of IL-8 production by β2-agonists has previously been shown to occur concom-
itantly with increased MKP-1 expression [46,47]. Accordingly, we found here that salbutamol
suppressed TNF production in macrophages along with increased MKP-1 expression and
decreased p38 MAPK phosphorylation. More interestingly, the current findings extend the
previous data by providing in vivo evidence that MKP-1 mediates the anti-inflammatory effects
of salbutamol, at least partly. Carrageenan-induced acute inflammatory response was inhibited
by salbutamol in wild-type mice, but that effect was impaired in MKP1(-/-) mice. This strongly
suggests that MKP-1 participates in the anti-inflammatory effects of β2-receptor agonists. In
this study, we found that β2-agonists were more potent inhibitors of TNF production as com-
pared to that seen with p38 MAPK inhibitor. This suggests that the anti-inflammatory effects
of β2-agonists are mediated not only through inhibition of p38 MAPK activity by MKP-1 but
there are other anti-inflammatory mechanisms involved, also. This is also supported by the
finding showing that the inhibition of carrageenan-induced inflammatory response by salbuta-
mol was partially but not completely, impaired in MKP-1(-/-) mice. For instance, cAMP has
been reported to inhibit macrophage phagocytosis through a cAMP effector Exchange protein
activated by cAMP-1 [48].
Importantly, MKP-1 is linked to certain other important anti-inflammatory drug effects.
The expression of MKP-1 is increased by glucocorticoids, and MKP-1 mediates, at least partly,
the anti-inflammatory effects of glucocorticoids [13,49]. Earlier it has been reported that long-
acting β2-agonists increased MKP-1 levels in airway smooth muscle cells [50].We have shown
that disease-modifying anti-rheumatic gold compounds enhance MKP-1 expression along
with their inhibitory effects on the production of IL-6, cyclooxygenase-2 and matrix metallo-
proteinase 3, and those effects were mediated by MKP-1 [14]. Recently, we have also demon-
strated that a PDE4 inhibitor rolipram increased MKP-1 levels and suppressed inflammatory
response in wild-type mice, but the inhibition of the inflammatory response was severely
impaired in MKP-1(-/-) mice [15]. Interestingly, we found here that combining rolipram to β2-
agonist further inhibited TNF production when compared to that with β2-agonist alone. This is
interesting because PDE4 inhibitor roflumilast is used as an anti-inflammatory remedy in
COPD and it increases cAMP levels by abrogating the enzymatic degradation of cAMP to
5’AMP [46,51,52]. This further supports the idea that the anti-inflammatory effects of β2-ago-
nists are mediated by cAMP and that combination of β2-agonist and PDE4 inhibitor would
have improved anti-inflammatory effect through enhanced MKP-1 expression.
Hence, MKP-1 is not only an endogenous suppressor of inflammatory response, but it also
seems to mediate therapeutic effects of certain anti-inflammatory drugs. Even though β2-recep-
tor agonists are primarily used as bronchodilators, they may also have anti-inflammatory
effects [19]. Increased MKP-1 expression could be a significant mechanism mediating the anti-
inflammatory effects of β2-receptor agonists. The present findings further emphasize the
potential of MKP-1 as a novel anti-inflammatory drug target, and its significance in the patho-
physiology and treatment of airway inflammation.
In conclusion, we found that β2-receptor agonists increased MKP-1 expression and sup-
pressed p38 MAPK phosphorylation (i.e. activity) as well as TNF production in macrophages.
Importantly, MKP-1 mediated the anti-inflammatory effects of salbutamol in vivo, and this is a
Anti-Inflammatory Effects of Beta2-Agonists Are Mediated by MKP-1
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novel finding. The results presented here emphasize the importance of MKP-1 as a novel anti-
inflammatory drug target.
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